LPTXAfter the bullish phase that ended at the end of 2023,
a bearish phase that could be concluded with a
long final wedge, so the bullish break of this figure
could be the signal of a bullish reversal,
otherwise towards new lows
LPTX trade ideas
Resistance become support LPTX already made breakout at the strongest resistance (3.02-3.16). Then, it also found to rebound back at the same level (resistance become support). From this point of view, the entry can be made at the range. The profit level found at 4.10 for 1st TP and 4.96 for 2nd TP. Drop you comment for further information about LPTX and have a nice day.
LPTX: Bullish Flag (60%)Bullish flag, not confirmed yet. Could confirm this coming week.
If confirmed:
Price target = 5.50$
Stay humble, have fun, make money!
$LPTX Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1 that is in multiple clinical trials for treating esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.
Leap Therapeutics Presents Updated Positive Data from the DisTinGuish Study of DKN-01 Plus Tislelizumab at the ESMO Congress
- DKN-01 plus tislelizumab and chemotherapy demonstrated compelling activity in first-line patients with gastric or gastroesophageal junction cancer
- Additional data presented today showed responses to treatment are independent of PD-L1 expression, with 79% ORR in patients with PD-L1 low (CPS < 5) tumors
- Company to host conference call on Friday, September 17, 2021 at 8:00 a.m. ET
CAMBRIDGE, Mass., Sept. 16, 2021 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the presentation of updated positive data from the first-line cohort of the DisTinGuish study, a Phase 2a clinical trial evaluating Leap's anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with tislelizumab, BeiGene Ltd.'s anti-PD-1 antibody, and chemotherapy, in patients with gastric or gastroesophageal junction cancer (G/GEJ), at the European Society for Medical Oncology (ESMO) Congress. The Company will host a conference call on Friday, September 17, 2021 to discuss preliminary results from the study.
The Company announced positive initial data from the DisTinGuish study on Monday, September 13, 2021 based on 25 G/GEJ patients enrolled in the trial that showed DKN-01 in combination with tislelizumab and chemotherapy as first-line therapy was well tolerated with compelling activity. The results presented at the ESMO Congress today included additional patient data stratified by tumoral PD-L1 expression levels based on visually-estimated combined positive score (vCPS), showing that robust objective clinical responses can be achieved from this combination regimen independently of PD-L1 expression.
"Initial data from this trial have shown that patients with high levels of DKK1 expression, a group with a poor prognosis, had encouraging responses to treatment. The additional data presented today show evidence that not only is DKK1 a critical biomarker in predicting response to DKN-01 and tislelizumab therapy, but also that the combination can induce deep responses regardless of the patient's PD-L1 status, including particularly poor prognosis patients with both low PD-L1 and high DKK1," said Samuel Klempner, MD, Member of the Faculty at Massachusetts General Hospital Cancer Center and Harvard Medical School. "Taken together, these are promising results for the combination therapy of DKN-01 with tislelizumab and chemotherapy in first line patients with gastric or gastroesophageal junction cancers."
About the DisTinGuish Study
The DisTinGuish study (NCT04363801) is a Phase 2a study of DKN-01 in combination with tislelizumab, an anti-PD-1 antibody, with or without chemotherapy as first-line or second-line therapy in patients with inoperable, locally advanced, G/GEJ adenocarcinoma. The study is being conducted in two parts in the United States and the Republic of Korea. Enrollment of Part A has been completed with 25 first-line HER2- G/GEJ cancer patients whose tumors express either high levels of DKK1 (DKK1-high) or low levels of DKK1 (DKK1-low). Part B of the study will enroll up to 48 patients with second-line, DKK1-high G/GEJ cancer. Leap is conducting this combination study as part of an exclusive option and license agreement with BeiGene for the development of DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
Key Findings
Among patients who received a full cycle of DKN-01 therapy, the ORR was 68.2%, with 90% ORR in DKK1-high patients and 56% in DKK1-low patients
Response was independent of PD-L1 expression, and particularly strong in the less favorable to checkpoint inhibitor therapy, PD-L1 low (vCPS < 5), population
DKK1 expression and PD-L1 expression are not correlated
Median duration of response and progression-free survival data are not yet mature, and patient follow-up continues
Twenty-five first-line patients were enrolled, and as of the cut-off date of the presentation, 15 patients had experienced a partial response (PR), six patients had a best response of stable disease (SD), one patient was non-evaluable for response (NE), and three patients were unable to complete a full cycle of DKN-01 therapy (non-modified ITT (mITT)).
Among the 21 patients that had RNAscope® DKK1 expression available, 12 were DKK1-high and 9 were DKK1-low .
Among the 20 patients that had PD-L1 expression available, 14 were PD-L1 low vCPS < 5 and 6 were PD-L1 high vCPS > 5 .
A copy of the poster presentation is available on the Company's website at www.leaptx.com
Conference Call
Leap will host a conference call on Friday, September 17, 2021 at 8:00 a.m. Eastern Time to further discuss the data. In addition to Leap's executive management team, Dr. Jaffer Ajani of M.D. Anderson Cancer Center and Dr. Samuel Klempner of Massachusetts General Hospital will be on the call. The call can be accessed by dialing (866) 589-0108 (U.S. and Canada) or (409) 231-2048 (international). The passcode for the conference call is 1729397. The presentation will be webcast live and may be accessed on the Investors page of the Company's website at investors.leaptx.com where a replay of the event will also be available for a limited time.
About Leap Therapeutics
Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap has entered into a strategic partnership with BeiGene, Ltd. for the rights to develop DKN-01 in Asia (excluding Japan), Australia, and New Zealand.
$LPTXBroke out of ascending triangle
Currently back-testing the break-out
4hr hidden bullish divergence on the MACD and RSI
Stop = below diagonal support
Target = Resistance
LPTX Inv. H&S within WedgeI am looking at a break of the $2.60 level to confirm breakout.
-Price tightening within wedge for 3+ months (depending on how you draw the wedge) and completing what appears to be the right shoulder of an IH&S. (The midline, as I have drawn it, fits very neatly).
-Price has recently experienced bullish diverging of EMAs with recent strong support found at the 50 EMA (purple) which also happened to be the midline of the H&S pattern.
-Price is coming off of .786 retacement from move off Nov '19 lows which tells me the stock may be in a potentially bullish impulse move
-Currently testing VWAP from the high on 2/19/20
-MACD upward trajectory appears very aggressive.
I like this one over $2.60. Assuming LPTX is indeed in the midst of a wave 3, and the .786 retrace was the wave 2 pullback, I have measured the minimum target as a 1.0 extension to the Wave 2 low which = $3.8.
Bullish SharkLeap is looking to make another leap. Harmonic shark patterns leave more room for volatility trades and make for high reward scenario's when traded correctly.
As of today (09-04-2019), 84,220 of the 261,828 shares traded where short. This is equivalent to a sizable 32.17% short percent.
The technical's are now aligning with some key dates with a potential short squeeze on its way (assuming good data).
$LPTX is trading at the lower end of the long-term trading range.
Bullish harmonic shark pattern, look for profit taking and/ or chances to add at the 382 and 50 retracement levels to ride up to the top of the range.
Not only does this trade have massive upside potential for a swing trade, it is also showing confluence with Fibonacci time-cycles, fib-retracement and trend.
Tip of the day: Learning how to be disciplined is vital to trading volatility. Follow our trading team for ideas on how to stay more disciplined in biotech.
Disclosure: I have no position in LPTX. I may buy or sell in the next 72 hours. This is not a note to but or sell. Please do your homework before investing.
LPTX Technical Analysis Possible retracement to 200-Day MA ($3.00). Series of higher lows on the 2-month chart!
LPTX - BREAK OUT - POSSIBLE 40% MOVELeap Therapeutics, Inc., formerly HealthCare Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor (GITR). DKN-01 has potential as a targeted cancer treatment in esophageal cancer, cholangiocarcinoma, non-small cell lung cancer, and other tumor types, such as pancreatic, gastric, liver, head and neck, uterine, and prostate cancers and multiple myeloma. It is conducting two clinical trials of TRX518 in patients with advanced solid tumors and have evidence of biomarker modulation and clinical activity. DKN-01 has been tested in a pilot study in patients with multiple myeloma in combination with lenalidomide and dexamethasone. .
Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that it will host a conference call on August 6, 2019, to provide a program update for DKN-01, a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01 is in clinical trials in patients with esophagogastric, hepatobiliary, gynecologic, and prostate cancers. (Source: finance.yahoo.com)
SHORT INTEREST
2.1M 07/15/19
P/E Current
-0.95
P/E Ratio (with extraordinary items)
-1.34
Average Recommendation: BUY
Average Target Price: 9.00
$LPTX BIG MOVE EXPECTED TODAY 30% TARGET *****SPECULATION IS WE COULD GET A SIZEABLE MOVE IN THE STOCK TODAY WITH W EASY 30% GAIN*********************
SET ALERTS FOR A POSSIBLE MOVE TO ABOVE $2
AVERAGE PRICE TARGET $9
AVERAGE RECOMMENDATION buy
LEAP THERAPEUTICS INC.
Leap Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies designed to treat patients with cancer. Its clinical stage programs are DKN-01 and TRX518.
#LPTX #long #stockLPTX has formed an inverse head and shoulders. Stocks like this are challenging to assess. They just do not have the technical history required. Never the less, i think this could be a solid play. Massive inverse H&S with ok indicator conformation.
